Page last updated: 2024-12-06

ddms

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DDMS: a water soluble and highly specific inhibitor of cytochrome P-450 omega-hydroxylase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17532
CHEBI ID28555
SCHEMBL ID7201656
MeSH IDM0302564

Synonyms (37)

Synonym
BB 0259624
1,1'-(2-chloroethane-1,1-diyl)bis(4-chlorobenzene)
1-chloro-4-[2-chloro-1-(4-chlorophenyl)ethyl]benzene
CHEBI:28555
p,p'-ddms
1,1-bis(p-chlorophenyl)-2-chloroethane
1-chloro-2,2-bis(4-chlorophenyl)ethane
1,1'-(2-chloroethylidene)bis(4-chloro)benzene
1-chloro-2,2-bis(p-chlorophenyl)ethane
benzene, 1,1'-(2-chloroethylidene)bis-4-chloro-
1-chloro-2,2-bis(4'-chlorophenyl)ethane (ddms)
ai3-07690
benzene, 1,1'-(2-chloroethylidene)bis(4-chloro)-
hsdb 2829
brn 1979260
ethane, 2,2-bis(p-chlorophenyl)-1-chloro-
benzene, 1,1'-(2-chloroethylidene)bis(4-chloro-
ethane, 2-chloro-1,1-bis(p-chlorophenyl)-
2,2-bis(p-chlorophenyl)-1-monochloroethane
1-chloro-2,2-bis(4'-chlorophenyl)ethane
ddms
C06638
2642-80-0
b7rxr6o461 ,
unii-b7rxr6o461
AKOS016344232
p,p'-ddms [hsdb]
1,1-di(4-chlorophenyl)-2-chloroethane
SCHEMBL7201656
benzene, 1,1'-(2-chloroethylidene)bis[4-chloro-
1-chloro-4-[2-chloro-1-(4-chlorophenyl)ethyl]benzene #
CHBOSHOWERDCMH-UHFFFAOYSA-N
DTXSID1074757
2,2-bis(4-chlorophenyl)-1-chloroethane
Q27103769
CS-0116648
ddms(p,p')

Research Excerpts

Overview

DDMS is a rare cause of epilepsy and should be considered and excluded in cases of refractory seizures. Several questions regarding this disease remain unanswered.

ExcerptReferenceRelevance
"DDMS is a rare cause of epilepsy and should be considered and excluded in cases of refractory seizures."( Dyke-davidoff-masson syndrome: A case report of an adolescent boy at a tertiary hospital in Adamawa, North-Eastern Nigeria.
C Dahiru, AM; Emmanuel, P; Hirayama, K; Manchan, DB; Namuya, NP; Raheem, N; Usman, AB; Usman, AU, 2022
)
1.44
"DDMS is a rare syndrome, and several questions regarding this disease remain unanswered. "( Dyke-Davidoff-Masson Syndrome: Main clinical and radiological findings- systematic literature review.
Centeno, RS; de Aguiar, PHP; Hsu, BRRHS; Rondão, MBA, 2023
)
2.35

Actions

ExcerptReferenceRelevance
"DDMS is a rare cause of epilepsy and should be considered and excluded in cases of refractory seizures."( Dyke-davidoff-masson syndrome: A case report of an adolescent boy at a tertiary hospital in Adamawa, North-Eastern Nigeria.
C Dahiru, AM; Emmanuel, P; Hirayama, K; Manchan, DB; Namuya, NP; Raheem, N; Usman, AB; Usman, AU, 2022
)
1.44

Treatment

DDMS treatment also restored the vasodilator response to reduced Po(2) that was impaired in arteries from rats on a HS diet. Treatment with DDMS or 20-HEDE greatly attenuated the constrictor responsiveness in vessels overexpressing CYP4A1.

ExcerptReferenceRelevance
"DDMS treatment also restored the vasodilator response to reduced Po(2) that was impaired in arteries from rats on a HS diet."( Effects of high-salt diet on CYP450-4A omega-hydroxylase expression and active tone in mesenteric resistance arteries.
de la Cruz, L; Falck, JR; Lombard, JH; Roman, RJ; Wang, J, 2005
)
1.05
"Treatment with DDMS or 20-HEDE greatly attenuated the constrictor responsiveness to both constrictor stimuli in vessels overexpressing CYP4A1, whereas the treatment had much less effect in control vessels."( Transfection of CYP4A1 cDNA decreases diameter and increases responsiveness of gracilis muscle arterioles to constrictor stimuli.
Falck, JR; Gopal, VR; Laniado-Schwartzman, M; Nasjletti, A; Wang, JS; Wang, MH; Zand, B; Zhang, F, 2004
)
0.66

Bioavailability

ExcerptReferenceRelevance
" Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury."( Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.
Certíková Chábová, V; Cervenka, L; Falck, JR; Hammock, BD; Imig, JD; Kompanowska-Jezierska, E; Kopkan, L; Kramer, HJ; Kujal, P; Sadowski, J; Vanecková, I; Vanourková, Z; Vernerová, Z; Walkowska, A, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
"All DDT metabolites tested revealed a clear dose-response relationship for cytotoxicity in RTG-2 cells, but no dioxin-like activities with RTL-W1 cells."( Toxicity, dioxin-like activities, and endocrine effects of DDT metabolites--DDA, DDMU, DDMS, and DDCN.
Braunbeck, T; Erdinger, L; Hallare, AV; Hollert, H; Otte, JC; Rastall, A; Ricking, M; Schwarzbauer, J; Wetterauer, B, 2012
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
chlorophenylethaneAny chlorohydrocarbon that is phenylethane substituted by at least one chloro group at unspecified position.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (5.77)18.2507
2000's40 (76.92)29.6817
2010's4 (7.69)24.3611
2020's5 (9.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 86.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index86.24 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index147.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (86.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (5.77%)6.00%
Case Studies2 (3.85%)4.05%
Observational0 (0.00%)0.25%
Other47 (90.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]